Cyclooxygenase-2 and Epidermal Growth Factor Receptor: Pharmacologic Targets for Chemoprevention
Top Cited Papers
- 10 January 2005
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (2) , 254-266
- https://doi.org/10.1200/jco.2005.09.112
Abstract
Understanding the mechanisms underlying carcinogenesis provides insights that are necessary for the development of therapeutic strategies to prevent cancer. Chemoprevention, the use of drugs or natural substances to inhibit carcinogenesis, is a rapidly evolving aspect of cancer research. Evidence is presented that cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) are potential pharmacologic targets to prevent cancer. In this paper, we review key data implicating a causal relationship between COX-2, EGFR, and carcinogenesis and possible mechanisms of action. We discuss evidence of crosstalk between COX-2 and EGFR in order to strengthen the rationale for combination chemoprevention, and review plans for a clinical trial that will evaluate the concept of combination chemoprevention targeting COX-2 and EGFR.Keywords
This publication has 90 references indexed in Scilit:
- Celecoxib, a Selective Cyclo-Oxygenase-2 Inhibitor, Enhances the Response to Preoperative Paclitaxel and Carboplatin in Early-Stage Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Cyclooxygenase-2 Is Overexpressed in HER-2/neu-positive Breast CancerJournal of Biological Chemistry, 2002
- Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cellsJournal of Clinical Investigation, 2001
- Global cancer statistics in the year 2000The Lancet Oncology, 2001
- Cot Kinase Induces Cyclooxygenase-2 Expression in T Cells through Activation of the Nuclear Factor of Activated T CellsJournal of Biological Chemistry, 2001
- The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous PolyposisNew England Journal of Medicine, 2000
- Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin‐1: a potential mechanism for inflammatory angiogenesisPublished by Wiley ,2000
- Thromboxane A2 is a mediator of COX-2 dependent endothelial migration & angiogenesisProstaglandins & Other Lipid Mediators, 1999
- Growth Factor Synthesis and Human Breast Cancer ProgressionJNCI Journal of the National Cancer Institute, 1995
- Prostaglandin synthetase dependent activation of 7,8-dihydro-7,8-dihydroxy-benzo(a)pyrene to mutagenic derivativesBiochemical and Biophysical Research Communications, 1978